Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Chmp symbols : Nvsef save search
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.17%
H: 0.28%
C: -0.01%
fabhalta first chmp positive novartis
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
Published: 2023-09-18 (Crawled : 06:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: -1.31%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.06%
H: 0.09%
C: -0.6%
biosimilar chmp breast positive cancer
Sandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumab
Published: 2023-07-24 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.05%
H: 0.24%
C: -0.83%
biosimilar chmp positive sclerosis
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
Published: 2023-03-31 (Crawled : 12:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.95%
H: 2.14%
C: 2.14%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.22%
H: 0.45%
C: 0.24%
chmp positive novartis heart
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Published: 2023-01-30 (Crawled : 07:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.65%
H: 0.37%
C: -0.48%
biosimilar chmp positive
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
scemblix treatment chmp novartis leukemia positive
Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer
Published: 2022-04-22 (Crawled : 14:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
tabrecta chmp novartis positive cancer
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.